SCHEMBL21393062

SCHEMBL21393062

O=C(CCl)N1CCN(c2ncc(Cl)cc2Cl)CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 3/20 0.54
MAPT P10636 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
LMNA P02545 2/20 0.50
HTT P42858 1/20 0.50
PHGDH O43175 1/20 0.47
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
P2RY12 Q9H244 4/20 0.43
KDM4E B2RXH2 1/20 0.43
GPX4 P36969 1/20 0.43
POLB P06746 1/20 0.42
GRM5 P41594 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27829814 0.85 PHGDH (0.51) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL14735155 0.84 PHGDH (0.50) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL2119358 0.83 SMN1; SMN2 (0.78) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL18362064 0.82 PHGDH (0.52) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL2289613 0.80 KMT2A (0.61) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL2289609 0.79 P2RY12 (0.47) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL3075186 0.79 CNR2 (0.47) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL20348529 0.79 PHGDH (0.49) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL20965429 0.78 PHGDH (0.46) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL2366192 0.76 MEN1 (0.55) KMT2ASMN1; SMN2ALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 KMT2A 3168/4885SMN1; SMN2 3721/4885ALDH1A1 4188/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 KMT2A 501/4885SMN1; SMN2 1834/4885ALDH1A1 2969/4885
US-11666661-B2 Methods and compounds for targeted autophagy ATG7, BECN1, SQSTM1 KMT2A 3168/4885SMN1; SMN2 3721/4885ALDH1A1 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.